Ryota Kawai
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Ryota Kawai has a total of 122 co-authors. Here are the top co-authors by number of shared publications:
Ayumi Shintani
Osaka Metropolitan University Graduate School of Medicine
6 shared publications- Ayumi Shintani
Department of Medical Statistics, Graduate School of Medicine, Osaka Metropolitan University, Osaka, Japan
6 shared publications - Hisako Yoshida
Department of Medical Statistics, Osaka Metropolitan University Graduate School of Medicine, Osaka, Japan
5 shared publications - Yasutaka Ihara
Clinical Research Promotion Unit, Clinical Therapeutic Trial Center Ehime University Hospital Toon Ehime Japan
4 shared publications - Ayumi Shintani
Department of Medical Statistics, Graduate School of Medicine, Osaka Metropolitan University, Osaka 545-8585, Japan
3 shared publications - Hiroshi Kakeya
Department of Infection Control and Prevention, Osaka Metropolitan University Hospital, Osaka, Japan; Department of Infection Control Science, Graduate School of Medicine, Osaka Metropolitan University, Osaka, Japan
3 shared publications
Latest Publications
- Open Access
- 29 September 2026
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 21 (9) , e0359100
Prognostic impact of postoperative complications among elderly patients with gastric cancer
Background: Japan’s rapidly aging population has led to an increase in elderly patients undergoing gastrectomy for gastric cancer. However, the impact of postoperative complications on survival in patients aged ≥80 years remains unclear. This study aimed to evaluate the association between postoperative complications and survival outcomes in patients aged ≥80 years with gastric cancer. Materials and methods: We retrospectively analyzed 61 patients aged ≥80 years who underwent gastrectomy with D2 lymph node dissection between 1999 and 2020. Postoperative complications were classified according to the Clavien-Dindo (CD) classification into a “no or minor complication group” (CD Grade ≤ II, including no postoperative complications) and a “major complication group” (CD Grade ≥ III), and the impact of postoperative complications on survival outcomes were assessed. A subgroup analysis excluding macroscopic type 4 was also performed. Results: Postoperative complications occurred in 24 patients (39.3%), of which 8 (13.1%) experienced major complications. Patients in the major complication group had a significantly longer postoperative hospital stay, while other baseline characteristics were similar between groups. Kaplan–Meier analysis showed a trend toward poorer OS in the major complication group (P = 0.063), and recurrence-free survival (RFS) was significantly worse in this group (P = 0.004). Multivariate analysis showed that postoperative complications of CD grade ≥ III were independently associated with poorer OS (HR 2.51; 95% CI 1.01–6.24; P = 0.049). Subgroup analysis in patients without type 4 also showed significantly worse OS in the major complication group (P = 0.036). Conclusion: This study showed that postoperative complications were associated with poorer OS and RFS even in patients aged ≥80 years with gastric cancer. Future large-scale studies are needed to further clarify this association and optimize treatment strategies for this population.
- 29 September 2026
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 21 (9) , e0359100
Open AccessPrognostic impact of postoperative complications among elderly patients with gastric cancer
Background: Japan’s rapidly aging population has led to an increase in elderly patients undergoing gastrectomy for gastric cancer. However, the impact of postoperative complications on survival in patients aged ≥80 years remains unclear. This study aimed to evaluate the association between postoperative complications and survival outcomes in patients aged ≥80 years with gastric cancer. Materials and methods: We retrospectively analyzed 61 patients aged ≥80 years who underwent gastrectomy with D2 lymph node dissection between 1999 and 2020. Postoperative complications were classified according to the Clavien-Dindo (CD) classification into a “no or minor complication group” (CD Grade ≤ II, including no postoperative complications) and a “major complication group” (CD Grade ≥ III), and the impact of postoperative complications on survival outcomes were assessed. A subgroup analysis excluding macroscopic type 4 was also performed. Results: Postoperative complications occurred in 24 patients (39.3%), of which 8 (13.1%) experienced major complications. Patients in the major complication group had a significantly longer postoperative hospital stay, while other baseline characteristics were similar between groups. Kaplan–Meier analysis showed a trend toward poorer OS in the major complication group (P = 0.063), and recurrence-free survival (RFS) was significantly worse in this group (P = 0.004). Multivariate analysis showed that postoperative complications of CD grade ≥ III were independently associated with poorer OS (HR 2.51; 95% CI 1.01–6.24; P = 0.049). Subgroup analysis in patients without type 4 also showed significantly worse OS in the major complication group (P = 0.036). Conclusion: This study showed that postoperative complications were associated with poorer OS and RFS even in patients aged ≥80 years with gastric cancer. Future large-scale studies are needed to further clarify this association and optimize treatment strategies for this population.
- Open Access
Efficacy and Safety of Sakurajima Radish in Patients with Metabolic Syndrome: A Phase IIb Randomized, Three-Period Crossover Trial
Background/Objectives: We aimed to evaluate the efficacy and safety of a short-term dietary intervention using trigonelline-rich Sakurajima radish on vascular endothelial function in patients with metabolic syndrome (MetS). Methods: In this multicenter, open-label, randomized, three-period crossover phase IIb trial, 21 patients with MetS were assigned to three 14-day sequences (Sakurajima radish powder, Aokubi radish powder, and a usual diet), separated by 14-day washouts. The primary outcome was flow-mediated dilation (FMD). Key Secondary outcomes included blood pressure (BP), urinary nitric oxide metabolites (NOx), and the oxidative stress marker 8-hydroxy-2′-deoxyguanosine (8-OHdG). Results: Sakurajima radish did not improve FMD versus the usual diet (p = 0.58) or Aokubi radish (p = 0.59), although a significant negative carryover effect following the Aokubi period likely confounded this estimation. Despite successfully stimulating NO production (elevated urinary NOx, p = 0.03), the intervention paradoxically increased oxidative stress (elevated 8-OHdG/creatinine, p = 0.02) and significantly elevated systolic BP compared with the usual diet (+9.67 mmHg, p = 0.03) and Aokubi radish (+8.86 mmHg, p = 0.04). Conclusions: Sakurajima radish does not appear to improve endothelial function in patients with MetS within the constraints of this short-term crossover design. Importantly, the unexpected negative carryover effect inherently limits the interpretability of this primary FMD outcome, as it may have masked potential physiological benefits. Despite boosting NO production, the intervention paradoxically exacerbated systemic oxidative stress and elevated systolic BP. These findings suggest that in the pro-oxidant environment of MetS, NO-boosting functional foods may induce unintended adverse hemodynamic responses, underscoring the need for careful risk–benefit evaluation and parallel-group trial designs in this specific population.
Open AccessEfficacy and Safety of Sakurajima Radish in Patients with Metabolic Syndrome: A Phase IIb Randomized, Three-Period Crossover Trial
Background/Objectives: We aimed to evaluate the efficacy and safety of a short-term dietary intervention using trigonelline-rich Sakurajima radish on vascular endothelial function in patients with metabolic syndrome (MetS). Methods: In this multicenter, open-label, randomized, three-period crossover phase IIb trial, 21 patients with MetS were assigned to three 14-day sequences (Sakurajima radish powder, Aokubi radish powder, and a usual diet), separated by 14-day washouts. The primary outcome was flow-mediated dilation (FMD). Key Secondary outcomes included blood pressure (BP), urinary nitric oxide metabolites (NOx), and the oxidative stress marker 8-hydroxy-2′-deoxyguanosine (8-OHdG). Results: Sakurajima radish did not improve FMD versus the usual diet (p = 0.58) or Aokubi radish (p = 0.59), although a significant negative carryover effect following the Aokubi period likely confounded this estimation. Despite successfully stimulating NO production (elevated urinary NOx, p = 0.03), the intervention paradoxically increased oxidative stress (elevated 8-OHdG/creatinine, p = 0.02) and significantly elevated systolic BP compared with the usual diet (+9.67 mmHg, p = 0.03) and Aokubi radish (+8.86 mmHg, p = 0.04). Conclusions: Sakurajima radish does not appear to improve endothelial function in patients with MetS within the constraints of this short-term crossover design. Importantly, the unexpected negative carryover effect inherently limits the interpretability of this primary FMD outcome, as it may have masked potential physiological benefits. Despite boosting NO production, the intervention paradoxically exacerbated systemic oxidative stress and elevated systolic BP. These findings suggest that in the pro-oxidant environment of MetS, NO-boosting functional foods may induce unintended adverse hemodynamic responses, underscoring the need for careful risk–benefit evaluation and parallel-group trial designs in this specific population.
- Open Access
- 3 May 2026
- Published by Elsevier in Lung Cancer
- Vol. 217, 109432
Phase II study of ramucirumab plus erlotinib for treatment-naïve patients with EGFR-mutant non-squamous non-small cell lung cancer and pleural effusion (RELAY-Effusion)
- 3 May 2026
- Published by Elsevier in Lung Cancer
- Vol. 217, 109432
Open AccessPhase II study of ramucirumab plus erlotinib for treatment-naïve patients with EGFR-mutant non-squamous non-small cell lung cancer and pleural effusion (RELAY-Effusion)
- Open Access
- 28 April 2026
- Published by MDPI AG in Preprints.org
Clinical Trial on the Efficacy and Safety of Sakurajima Radish for Vascular Endothelial Function: A Phase IIb Open-Label, Randomized, Three-Sequence Three-Period Crossover Study with Regular Diet and Aokubi Radish Controls
Background/Objectives: We aimed to evaluate the efficacy and safety of trigonelline-rich Sakurajima radish on vascular endothelial function in patients with metabolic syndrome (MetS). Methods: In this multicenter, open-label, randomized, three-period crossover phase IIb trial, 21 patients with MetS were assigned to three 14-day sequences: Sakurajima radish powder, Aokubi radish powder, and a usual diet, separated by 14-day washouts. The primary outcome was flow-mediated dilation (FMD). The secondary outcomes included blood pressure (BP), urinary nitric oxide metabolites (NOx), and oxidative stress markers (8-hydroxy-2′-deoxyguanosine [8-OHdG]). Results: Twenty-one participants were included in this study. Sakurajima radish did not significantly improve FMD compared with the usual diet (control) (p = 0.58) or Aokubi radish (p=0.59). Unexpectedly, systolic BP was significantly higher with Sakurajima radish compared with control (+9.67 mmHg, p = 0.03) and Aokubi radish (+8.86 mmHg, p = 0.04). Urinary 8-OHdG/creatinine levels were also significantly higher with Sakurajima radish compared with control (p = 0.02), despite a significant elevation in urinary NOx levels (p = 0.03). A significant negative carryover effect on FMD was observed after the Aokubi radish period. Conclusions: Consumption of Sakurajima radish does not improve endothelial function in patients with MetS. Contrary to expectations, the intervention is associated with increased systolic BP and oxidative stress, despite elevated NOx levels. These findings suggest the need for caution regarding its cardiovascular application in patients with MetS .
- 28 April 2026
- Published by MDPI AG in Preprints.org
Open AccessClinical Trial on the Efficacy and Safety of Sakurajima Radish for Vascular Endothelial Function: A Phase IIb Open-Label, Randomized, Three-Sequence Three-Period Crossover Study with Regular Diet and Aokubi Radish Controls
Background/Objectives: We aimed to evaluate the efficacy and safety of trigonelline-rich Sakurajima radish on vascular endothelial function in patients with metabolic syndrome (MetS). Methods: In this multicenter, open-label, randomized, three-period crossover phase IIb trial, 21 patients with MetS were assigned to three 14-day sequences: Sakurajima radish powder, Aokubi radish powder, and a usual diet, separated by 14-day washouts. The primary outcome was flow-mediated dilation (FMD). The secondary outcomes included blood pressure (BP), urinary nitric oxide metabolites (NOx), and oxidative stress markers (8-hydroxy-2′-deoxyguanosine [8-OHdG]). Results: Twenty-one participants were included in this study. Sakurajima radish did not significantly improve FMD compared with the usual diet (control) (p = 0.58) or Aokubi radish (p=0.59). Unexpectedly, systolic BP was significantly higher with Sakurajima radish compared with control (+9.67 mmHg, p = 0.03) and Aokubi radish (+8.86 mmHg, p = 0.04). Urinary 8-OHdG/creatinine levels were also significantly higher with Sakurajima radish compared with control (p = 0.02), despite a significant elevation in urinary NOx levels (p = 0.03). A significant negative carryover effect on FMD was observed after the Aokubi radish period. Conclusions: Consumption of Sakurajima radish does not improve endothelial function in patients with MetS. Contrary to expectations, the intervention is associated with increased systolic BP and oxidative stress, despite elevated NOx levels. These findings suggest the need for caution regarding its cardiovascular application in patients with MetS .
- 25 March 2026
- Published by Wiley in The Journal of Dermatology
- Vol. 53 (5) , 818-823
Analysis of Medical Costs of Melanoma Using a Japanese National Database
The advent of immune checkpoint inhibitors (ICIs) and targeted therapeutic agents (TTAs) has improved melanoma treatment. With the ongoing development of novel drugs, treatment options are expected to expand further. However, this is also anticipated to increase the financial burden on patients. Changes in medical costs for melanoma patients have not yet been examined in Japan. Therefore, we herein conducted a retrospective observational study using data from a Japanese nationwide database. The dataset comprised 14 727 patients diagnosed with melanoma between April 2008 and June 2023. The mean monthly cost per patient was calculated and changes were evaluated. The results obtained showed that the mean monthly cost per patient has consistently increased, and a breakdown revealed that drug costs for ICIs and TTAs accounted for a significant percentage of these costs. Furthermore, the usage rates of ICIs and TTAs have steadily increased since their approval in 2014, with a notable rise being observed in 2018 when adjuvant therapies were approved in Japan. An interrupted time series analysis further confirmed a significant increase in medical costs around 2018. While ICIs and TTAs represent major advances in melanoma treatment, their increasing use underscores the need for a careful evaluation of both clinical benefits and economic sustainability.
- 25 March 2026
- Published by Wiley in The Journal of Dermatology
- Vol. 53 (5) , 818-823
Analysis of Medical Costs of Melanoma Using a Japanese National Database
The advent of immune checkpoint inhibitors (ICIs) and targeted therapeutic agents (TTAs) has improved melanoma treatment. With the ongoing development of novel drugs, treatment options are expected to expand further. However, this is also anticipated to increase the financial burden on patients. Changes in medical costs for melanoma patients have not yet been examined in Japan. Therefore, we herein conducted a retrospective observational study using data from a Japanese nationwide database. The dataset comprised 14 727 patients diagnosed with melanoma between April 2008 and June 2023. The mean monthly cost per patient was calculated and changes were evaluated. The results obtained showed that the mean monthly cost per patient has consistently increased, and a breakdown revealed that drug costs for ICIs and TTAs accounted for a significant percentage of these costs. Furthermore, the usage rates of ICIs and TTAs have steadily increased since their approval in 2014, with a notable rise being observed in 2018 when adjuvant therapies were approved in Japan. An interrupted time series analysis further confirmed a significant increase in medical costs around 2018. While ICIs and TTAs represent major advances in melanoma treatment, their increasing use underscores the need for a careful evaluation of both clinical benefits and economic sustainability.
- Open Access
- 1 January 2026
- Published by Japan Endocrine Society in Endocrine Journal
- Vol. 73 (1) , 53-62
Distribution of blood pressure and its positive association with body mass index standard deviation score in pediatric patients with X-linked hypophosphatemia: a sub-group analysis from the SUNFLOWER observational study
Few studies have investigated the distribution of blood pressure (BP) and associated factors in pediatric patients with X-linked hypophosphatemic rickets (XLH). We analyzed snapshot baseline data from the SUNFLOWER study, a longitudinal observational cohort study of patients with XLH in Japan and South Korea (NCT03745521/UMIN000031605). We used data from pediatric participants aged 5–17 years who were 120–189.9 cm (males) and 120–179.9 cm (females) in height and had a history of conventional treatment. Systolic and diastolic BP (SBP and DBP, respectively) were categorized into percentile ranks based on age, sex, and height. Ordinal logistic regression analyses were performed to investigate the association between BP and exposure factors, including estimated glomerular filtration rate, serum intact parathyroid hormone levels, serum intact fibroblast growth factor 23 levels, urinary calcium/creatinine ratio, and body mass index standard deviation score (BMI-SDS). Forty-five participants were eligible for the subgroup analysis. Of these, 44 were evaluated after one patient with missing BP data was excluded. After height adjustment, three patients (6.8%) were at or above the 95th percentile for SBP, and five (11.4%) were at or above the 95th percentile for DBP. Regarding age adjustment, one patient (2.3%) was at or above the 95th percentile for SBP and three (6.8%) were at or above the 95th percentile for DBP. In the association analysis, age- and height-adjusted BP was positively correlated with BMI-SDS. These results suggest that some pediatric patients with XLH exhibit high BP and that a high BMI-SDS may be a risk factor.
- 1 January 2026
- Published by Japan Endocrine Society in Endocrine Journal
- Vol. 73 (1) , 53-62
Open AccessDistribution of blood pressure and its positive association with body mass index standard deviation score in pediatric patients with X-linked hypophosphatemia: a sub-group analysis from the SUNFLOWER observational study
Few studies have investigated the distribution of blood pressure (BP) and associated factors in pediatric patients with X-linked hypophosphatemic rickets (XLH). We analyzed snapshot baseline data from the SUNFLOWER study, a longitudinal observational cohort study of patients with XLH in Japan and South Korea (NCT03745521/UMIN000031605). We used data from pediatric participants aged 5–17 years who were 120–189.9 cm (males) and 120–179.9 cm (females) in height and had a history of conventional treatment. Systolic and diastolic BP (SBP and DBP, respectively) were categorized into percentile ranks based on age, sex, and height. Ordinal logistic regression analyses were performed to investigate the association between BP and exposure factors, including estimated glomerular filtration rate, serum intact parathyroid hormone levels, serum intact fibroblast growth factor 23 levels, urinary calcium/creatinine ratio, and body mass index standard deviation score (BMI-SDS). Forty-five participants were eligible for the subgroup analysis. Of these, 44 were evaluated after one patient with missing BP data was excluded. After height adjustment, three patients (6.8%) were at or above the 95th percentile for SBP, and five (11.4%) were at or above the 95th percentile for DBP. Regarding age adjustment, one patient (2.3%) was at or above the 95th percentile for SBP and three (6.8%) were at or above the 95th percentile for DBP. In the association analysis, age- and height-adjusted BP was positively correlated with BMI-SDS. These results suggest that some pediatric patients with XLH exhibit high BP and that a high BMI-SDS may be a risk factor.
- Open Access
- 22 November 2025
- Published by Elsevier in Annals of Physical and Rehabilitation Medicine
- Vol. 69 (2) , 102035
Association between additional non-weekday rehabilitation and discharge function after hip fracture, modified by age and admission function: a retrospective study
- 22 November 2025
- Published by Elsevier in Annals of Physical and Rehabilitation Medicine
- Vol. 69 (2) , 102035
Open AccessAssociation between additional non-weekday rehabilitation and discharge function after hip fracture, modified by age and admission function: a retrospective study
- Open Access
A Preoperative Diagnostic Nomogram to Predict Tumor Subclassifications of Intrahepatic Cholangiocarcinoma
Background/Objectives: Intrahepatic cholangiocarcinoma (ICC) is subclassified into small and large duct types. Although these subclassifications may help determine the appropriate treatment strategy, subclassification diagnosis currently depends on postoperative pathological examinations. This study aimed to establish a nomogram to predict ICC subclassifications. Methods: This study included 126 patients with ICC who underwent liver resection. The participants were divided into small and large duct-type ICC groups. A nomogram to predict large duct-type ICC was developed using four diagnostic imaging findings: rim-type enhancement in the early phase, an absence of tumor enhancement in the early phase, the presence of peripheral biliary dilatation due to tumor invasion, the presence of penetrating Glisson’s vessels in the tumor, and two laboratory test results: serum gamma-glutamyl transpeptidase and carbohydrate antigen 19-9 levels. Nomogram performance was also assessed. Moreover, the bootstrap method and calibration plots were used to assess nomogram validity. Results: Seventy and fifty-six patients were pathologically diagnosed with small and large duct-type ICCs, respectively. The area under the curve of the established nomogram was 0.93 and remained 0.91 after Harrell’s bias correction. The sensitivity and specificity of the nomogram developed using the Youden index were higher than those of any of the characteristic imaging findings. Calibration plots demonstrated a strong association between the nomogram and the actual data. Conclusions: We developed a novel preoperative nomogram to predict large duct-type ICC. This nomogram can be clinically useful for predicting the subclassifications of ICCs and may contribute to the establishment of a more appropriate treatment strategy for ICC.
Open AccessA Preoperative Diagnostic Nomogram to Predict Tumor Subclassifications of Intrahepatic Cholangiocarcinoma
Background/Objectives: Intrahepatic cholangiocarcinoma (ICC) is subclassified into small and large duct types. Although these subclassifications may help determine the appropriate treatment strategy, subclassification diagnosis currently depends on postoperative pathological examinations. This study aimed to establish a nomogram to predict ICC subclassifications. Methods: This study included 126 patients with ICC who underwent liver resection. The participants were divided into small and large duct-type ICC groups. A nomogram to predict large duct-type ICC was developed using four diagnostic imaging findings: rim-type enhancement in the early phase, an absence of tumor enhancement in the early phase, the presence of peripheral biliary dilatation due to tumor invasion, the presence of penetrating Glisson’s vessels in the tumor, and two laboratory test results: serum gamma-glutamyl transpeptidase and carbohydrate antigen 19-9 levels. Nomogram performance was also assessed. Moreover, the bootstrap method and calibration plots were used to assess nomogram validity. Results: Seventy and fifty-six patients were pathologically diagnosed with small and large duct-type ICCs, respectively. The area under the curve of the established nomogram was 0.93 and remained 0.91 after Harrell’s bias correction. The sensitivity and specificity of the nomogram developed using the Youden index were higher than those of any of the characteristic imaging findings. Calibration plots demonstrated a strong association between the nomogram and the actual data. Conclusions: We developed a novel preoperative nomogram to predict large duct-type ICC. This nomogram can be clinically useful for predicting the subclassifications of ICCs and may contribute to the establishment of a more appropriate treatment strategy for ICC.
- 29 March 2025
- Published by Elsevier in Journal of Infection and Chemotherapy
- Vol. 31 (5) , 102689
Assessment of incidence and risk factors of COVID-19-associated candidemia using diagnosis procedure combination data
- 29 March 2025
- Published by Elsevier in Journal of Infection and Chemotherapy
- Vol. 31 (5) , 102689
Assessment of incidence and risk factors of COVID-19-associated candidemia using diagnosis procedure combination data
- Open Access
- 12 March 2025
- Published by Springer Nature in Calcified Tissue International
- Vol. 116 (1) , 1-11
Prevalence of Comorbid Hyperparathyroidism and Its Association with Renal Dysfunction in Asian Patients with X-Linked Hypophosphatemic Rickets/Osteomalacia
In patients with X-linked hypophosphatemic rickets/osteomalacia (XLH) in Asia, the current prevalence of hyperparathyroidism and its association with renal dysfunction have not been determined. We used patient data retrospectively collected up to the time of informed consent in the SUNFLOWER study, a long-term observational study, to investigate the current treatment status and prevalence of comorbid hyperparathyroidism and its association with renal dysfunction in patients with XLH in Japan and South Korea. Of 69 patients who met the eligibility criteria, 32 (46.4%) did not have hyperparathyroidism (hereinafter referred to as non-hyperparathyroidism), 33 (47.8%) had secondary hyperparathyroidism, and four (5.8%) had tertiary hyperparathyroidism. Men were more prone to develop secondary and tertiary hyperparathyroidism, use oral phosphate at higher frequencies, and have a higher incidence of Stage ≥ 3 chronic kidney disease and Grade ≥ 3 renal calcification than women. Ongoing treatments for patients with XLH and non-hyperparathyroidism, secondary hyperparathyroidism, and tertiary hyperparathyroidism mainly consisted of active vitamin D (30 [93.8%], 25 [75.8%], and 3 [75.0%], respectively) and oral phosphate (21 [65.6%], 23 [69.7%], and 4 [100.0%], respectively). At informed consent, patients with tertiary hyperparathyroidism had the lowest estimated glomerular filtration rate values. Our study highlights the prevalence of comorbid hyperparathyroidism and its association with renal dysfunction in patients with XLH through a large-scale observational study in Asia. Trial registration: NCT03745521; UMIN000031605.
- 12 March 2025
- Published by Springer Nature in Calcified Tissue International
- Vol. 116 (1) , 1-11
Open AccessPrevalence of Comorbid Hyperparathyroidism and Its Association with Renal Dysfunction in Asian Patients with X-Linked Hypophosphatemic Rickets/Osteomalacia
In patients with X-linked hypophosphatemic rickets/osteomalacia (XLH) in Asia, the current prevalence of hyperparathyroidism and its association with renal dysfunction have not been determined. We used patient data retrospectively collected up to the time of informed consent in the SUNFLOWER study, a long-term observational study, to investigate the current treatment status and prevalence of comorbid hyperparathyroidism and its association with renal dysfunction in patients with XLH in Japan and South Korea. Of 69 patients who met the eligibility criteria, 32 (46.4%) did not have hyperparathyroidism (hereinafter referred to as non-hyperparathyroidism), 33 (47.8%) had secondary hyperparathyroidism, and four (5.8%) had tertiary hyperparathyroidism. Men were more prone to develop secondary and tertiary hyperparathyroidism, use oral phosphate at higher frequencies, and have a higher incidence of Stage ≥ 3 chronic kidney disease and Grade ≥ 3 renal calcification than women. Ongoing treatments for patients with XLH and non-hyperparathyroidism, secondary hyperparathyroidism, and tertiary hyperparathyroidism mainly consisted of active vitamin D (30 [93.8%], 25 [75.8%], and 3 [75.0%], respectively) and oral phosphate (21 [65.6%], 23 [69.7%], and 4 [100.0%], respectively). At informed consent, patients with tertiary hyperparathyroidism had the lowest estimated glomerular filtration rate values. Our study highlights the prevalence of comorbid hyperparathyroidism and its association with renal dysfunction in patients with XLH through a large-scale observational study in Asia. Trial registration: NCT03745521; UMIN000031605.